Substrate Characterization and Outcomes of Catheter Ablation of Ventricular Arrhythmias in Patients With Mitral Annular Disjunction.


Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
09 2022
Historique:
pubmed: 9 9 2022
medline: 24 9 2022
entrez: 8 9 2022
Statut: ppublish

Résumé

Mitral annular disjunction (MAD) has recently been recognized as an arrhythmogenic entity. Data on the electrophysiological substrate as well as the outcomes of catheter ablation of ventricular arrhythmias in patients with MAD is limited. Forty patients with MAD (mean age 47±15 years; 70% female) underwent catheter ablation for ventricular arrhythmias. Detailed clinical, electrocardiographic, cardiac imaging, and procedural data were collected. Clinical outcomes were compared between patients who had substrate modification in the MAD area and those who did not. Twenty-three (57.5%) patients had ablation for premature ventricular contractions, 10 (25%) patients for sustained ventricular tachycardia, and 7 (17.5%) patients for premature ventricular contraction-triggered ventricular fibrillation. Mean end-systolic MAD length was 10.58±3.49 mm on transthoracic echocardiography. Seventeen (42.5%) patients had preprocedural cardiac magnetic resonance imaging, and 5 (29%) patients had late gadolinium enhancement. Among the 18 (45%) patients who had abnormal local electrograms (low voltage, long-duration, fractionated, isolated mid-diastolic potentials) during electroanatomical mapping, 10 (25%) patients had abnormal electrograms in the anterolateral mitral annulus and/or MAD area. Substrate modification was performed in 10 (25%) patients. Catheter ablation was acutely successful in 36 (90%) patients (elimination of premature ventricular contraction or noninducibility of ventricular tachycardia). After a median follow-up duration of 54.08 (interquartile range, 10.67-89.79) months, premature ventricular contraction burden decreased from a median of 9.75% (interquartile range, 3.25-14) before the ablation to a median of 4% (interquartile range, 1-7.75) after the ablation ( Patients with MAD have a complex arrhythmogenic substrate, and catheter ablation is effective in reducing recurrence of ventricular arrhythmias. Substrate mapping and ablation may be considered in these patients.

Sections du résumé

BACKGROUND
Mitral annular disjunction (MAD) has recently been recognized as an arrhythmogenic entity. Data on the electrophysiological substrate as well as the outcomes of catheter ablation of ventricular arrhythmias in patients with MAD is limited.
METHODS
Forty patients with MAD (mean age 47±15 years; 70% female) underwent catheter ablation for ventricular arrhythmias. Detailed clinical, electrocardiographic, cardiac imaging, and procedural data were collected. Clinical outcomes were compared between patients who had substrate modification in the MAD area and those who did not.
RESULTS
Twenty-three (57.5%) patients had ablation for premature ventricular contractions, 10 (25%) patients for sustained ventricular tachycardia, and 7 (17.5%) patients for premature ventricular contraction-triggered ventricular fibrillation. Mean end-systolic MAD length was 10.58±3.49 mm on transthoracic echocardiography. Seventeen (42.5%) patients had preprocedural cardiac magnetic resonance imaging, and 5 (29%) patients had late gadolinium enhancement. Among the 18 (45%) patients who had abnormal local electrograms (low voltage, long-duration, fractionated, isolated mid-diastolic potentials) during electroanatomical mapping, 10 (25%) patients had abnormal electrograms in the anterolateral mitral annulus and/or MAD area. Substrate modification was performed in 10 (25%) patients. Catheter ablation was acutely successful in 36 (90%) patients (elimination of premature ventricular contraction or noninducibility of ventricular tachycardia). After a median follow-up duration of 54.08 (interquartile range, 10.67-89.79) months, premature ventricular contraction burden decreased from a median of 9.75% (interquartile range, 3.25-14) before the ablation to a median of 4% (interquartile range, 1-7.75) after the ablation (
CONCLUSIONS
Patients with MAD have a complex arrhythmogenic substrate, and catheter ablation is effective in reducing recurrence of ventricular arrhythmias. Substrate mapping and ablation may be considered in these patients.

Identifiants

pubmed: 36074649
doi: 10.1161/CIRCEP.122.011088
doi:

Substances chimiques

Contrast Media 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e011088

Auteurs

Fatima M Ezzeddine (FM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Konstantinos C Siontis (KC)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

John Giudicessi (J)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Michael J Ackerman (MJ)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Ammar M Killu (AM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Abhishek J Deshmukh (AJ)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Malini Madhavan (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Martin van Zyl (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Vaibhav R Vaidya (VR)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Roshan Karki (R)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Andrew Tseng (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Thomas M Munger (TM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Christopher J McLeod (CJ)

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (C.J.M.).

Samuel J Asirvatham (SJ)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).
Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN (S.J.A.).

Freddy Del-Carpio Munoz (F)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.M.E., K.C.S., J.G., M.J.A., A.M.K., A.J.D., M.M., M.v.Z., V.R.V., R.K., A.T., T.M.M., S.J.A., F.D.-C.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH